Suanfarma Suanfarma

X

Find the latest Drugs in Development and Pipeline Prospector News of Park Therapeutics.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Park Therapeutics
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
45 South Park Place, Ste., 105 Morristown, NJ 07960
Telephone
Telephone
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Park Therapeutics is developing a unique, first-in-class, investigational NCE for the treatment of pain which is Phase III-ready. With the acquisition, Tris owns worldwide rights and all accompanying intellectual property for cebranopadol.


Lead Product(s): Cebranopadol

Therapeutic Area: Neurology Product Name: PRK-101

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Tris Pharma Inc

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition April 29, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY